Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Earnings Data
Report Date
May 12, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.89Last Year’s EPS
-4.2Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call emphasized significant strategic and clinical progress—regulatory alignment with EMA, Breakthrough/PRIME designations, full 12‑month follow-up on the pivotal dataset, initiation of CLR125 Phase 1b, strengthened IP and isotope supply, and material reductions in operating expenses that improved the company’s net loss profile. Offsetting these positives are a constrained cash position (cash runway only into 2026), the need for additional capital to initiate certain programs (notably CLR225) and execute confirmatory trials, reliance on enrollment and regulatory timing for near‑term milestones, and a substantial drop in other (non‑cash) income. Overall, the company made meaningful de‑risking and value-creation moves but faces near-term financing and execution risks.Company Guidance
Regulatory Progress for Lead Asset (iapocine I-131)
Achieved regulatory alignment with EMA (SAWP guidance) and plan to submit a conditional marketing authorization (CMA) in 2026 with potential European commercialization as early as 2027. FDA engagement supports pursuing an NDA under the accelerated approval pathway; Breakthrough Therapy designation in the U.S. and PRIME designation in the EU. Full 12-month follow-up on CLOVER‑WaM dataset now collected, strengthening the dossier for both accelerated approval and confirmatory trial design.
Clinical Pipeline Advancement (CLR125 & CLR225)
Initiated Phase 1b dose-finding study of CLR125 (iodine-125 Auger emitter) in triple-negative breast cancer; early interim dosimetry, safety, and preliminary efficacy data expected mid‑2026. CLR225 (alpha emitter) completed IND‑enabling work and is ready for Phase 1 pending funding. Preclinical pancreatic cancer models for CLR225 showed compelling tumor inhibition. Plan to present additional clinical outcomes (ORR, DOR, PFS, subsets) throughout 2026.
Expanded Intellectual Property and Isotope Supply
Significant expansion of global patent estate with new patents issued across Europe, Asia Pacific, Middle East and the Americas protecting lead asset, CLR125, and the PDC platform. Strengthened isotope supply chain via partnerships with ITM Technologies and Ionectics to secure commercial-scale access to 225Ac and astatine‑211 for alpha program development.
Improved Financial Efficiency and Capital Raises
Raised approximately $15.2 million during 2025 (including $5.8M in Q4). Reduced operating costs: reported R&D expense declined from $26.6M (2024) to $11.5M (2025) (~56.8% reduction) and SG&A declined from $25.6M to $11.5M (~55.1% reduction). Net loss improved to $21.8M in 2025 from $44.6M in 2024 (a ~51.1% reduction); net loss per basic share decreased from $36.52 to $8.35 (~77.1% reduction).
Commercial/Logistical Advantages
Established global logistical chain from prior international trial experience (≈25 European sites) and a competitive product shelf-life advantage (21 days at room temperature versus typical 3–7 days), facilitating broader and more flexible distribution. Company pursuing commercial partnerships in Europe rather than direct commercialization.
CLRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 04, 2026 | $2.68 | $2.90 | +8.21% |
Nov 13, 2025 | $3.50 | $2.87 | -18.00% |
Aug 14, 2025 | $4.42 | $4.42 | 0.00% |
May 13, 2025 | $7.92 | $7.20 | -9.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cellectar Biosciences (CLRB) report earnings?
Cellectar Biosciences (CLRB) is schdueled to report earning on May 12, 2026, TBA (Confirmed).
What is Cellectar Biosciences (CLRB) earnings time?
Cellectar Biosciences (CLRB) earnings time is at May 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLRB EPS forecast?
CLRB EPS forecast for the fiscal quarter 2026 (Q1) is -1.89.